| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1019 | 2019 |
| Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients M Delaunay, J Cadranel, A Lusque, N Meyer, V Gounant, D Moro-Sibilot, ... European Respiratory Journal 50 (2), 2017 | 383 | 2017 |
| Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer F Mosele, B Stefanovska, A Lusque, AT Dien, I Garberis, N Droin, ... Annals of Oncology 31 (3), 377-386, 2020 | 230 | 2020 |
| PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab N Guibert, M Delaunay, A Lusque, N Boubekeur, I Rouquette, E Clermont, ... Lung Cancer 120, 108-112, 2018 | 218 | 2018 |
| Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner JN Bianco, V Bergoglio, YL Lin, MJ Pillaire, AL Schmitz, J Gilhodes, ... Nature communications 10 (1), 910, 2019 | 125 | 2019 |
| Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial T Bachelot, T Filleron, I Bieche, M Arnedos, M Campone, F Dalenc, ... Nature Medicine 27 (2), 250-255, 2021 | 100 | 2021 |
| Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY) V Diéras, E Deluche, A Lusque, B Pistilli, T Bachelot, JY Pierga, F Viret, ... Cancer Research 82 (4_Supplement), PD8-02-PD8-02, 2022 | 83 | 2022 |
| Genomics to select treatment for patients with metastatic breast cancer F Andre, T Filleron, M Kamal, F Mosele, M Arnedos, F Dalenc, MP Sablin, ... Nature 610 (7931), 343-348, 2022 | 80 | 2022 |
| Combining nivolumab and ipilimumab with infliximab or certolizumab in patients with advanced melanoma: first results of a phase Ib clinical trial A Montfort, T Filleron, M Virazels, C Dufau, J Milhès, C Pagès, P Olivier, ... Clinical Cancer Research 27 (4), 1037-1047, 2021 | 68 | 2021 |
| Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial F Mosele, E Deluche, A Lusque, L Le Bescond, T Filleron, Y Pradat, ... Nature medicine 29 (8), 2110-2120, 2023 | 65 | 2023 |
| Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). J Mazieres, AE Drilon, L Mhanna, J Milia, A Lusque, AB Cortot, ... Journal of Clinical Oncology 36 (15_suppl), 9010-9010, 2018 | 61 | 2018 |
| LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial MF Mosele, A Lusque, V Dieras, E Deluche, A Ducoulombier, B Pistilli, ... Annals of Oncology 33, S123, 2022 | 54 | 2022 |
| Subventricular zones: new key targets for glioblastoma treatment J Khalifa, F Tensaouti, A Lusque, B Plas, JA Lotterie, A Benouaich-Amiel, ... Radiation Oncology 12, 1-11, 2017 | 51 | 2017 |
| Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: a propensity score-matched analysis E Pons-Tostivint, Y Kirova, A Lusque, M Campone, J Geffrelot, C Mazouni, ... Annals of Surgical Oncology 26, 356-365, 2019 | 48 | 2019 |
| Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort T Grinda, N Joyon, A Lusque, S Lefèvre, L Arnould, F Penault-Llorca, ... NPJ breast cancer 7 (1), 41, 2021 | 44 | 2021 |
| The RAS‐related GTP ase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism O Calvayrac, J Mazières, S Figarol, C Marty‐Detraves, I Raymond‐Letron, ... EMBO molecular medicine 9 (2), 238-250, 2017 | 36 | 2017 |
| Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients P Campredon, C Mouly, A Lusque, L Bigay-Game, E Bousquet, ... La Presse Médicale 48 (4), e199-e207, 2019 | 34 | 2019 |
| Body mass index as a major risk factor for severe breast cancer-related lymphedema H Leray, J Malloizel-Delaunay, A Lusque, E Chantalat, L Bouglon, ... Lymphatic Research and Biology 18 (6), 510-516, 2020 | 33 | 2020 |
| Breast desmoid tumor management in France: toward a new strategy L Duazo-Cassin, S Le Guellec, A Lusque, E Chantalat, M Laé, P Terrier, ... Breast cáncer Research and Treatment 176, 329-335, 2019 | 33 | 2019 |
| Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY) V Diéras, E Deluche, A Lusque, B Pistilli, T Bachelot, JY Pierga, F Viret, ... San Antonio Breast Cancer Symposium, 7-10, 2021 | 32 | 2021 |
